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Abstract
Background: Systemic inflammation impairs outcome in stroke patients and experimental animals via mechanisms
which are poorly understood. Circulating inflammatory mediators can activate cerebrovascular endothelium or glial
cells in the brain and impact on ischaemic brain injury. One of the most serious early clinical complications of
cerebral ischaemia is brain oedema, which compromises survival in the first 24-48 h. It is not understood whether
systemic inflammatory challenges impair outcome after stroke by increasing brain injury only or whether they have
direct effects on brain oedema, cerebrovascular inflammation and blood-brain barrier damage.
Methods: We used two different systemic inflammatory stimuli, acute endotoxin treatment and anaphylaxis to
study mechanisms of brain injury after middle cerebral artery occlusion (MCAo). Ischaemic brain injury, blood-brain
barrier damage and oedema were analysed by histological techniques. Systemic cytokine responses and
inflammatory changes in the brain were analysed by cytometric bead array, immunofluorescence, in situ
hibridization and quantitative real-time PCR.
Results: Systemic inflammatory challenges profoundly impaired survival in the first 24 h after experimental stroke
in mice, independently of an increase in infarct size. Systemic lipopolysaccharide (LPS) dose-dependently increased
mortality (50-100%) minutes to hours after cerebral ischaemia. Acute anaphylactic challenge in ovalbumin-
sensitised mice affected stroke more seriously when induced via intraperitoneal administration compared to
intravenous. Both LPS and anaphylaxis induced inflammatory changes in the blood and in the brain prior to
experimental stroke. Plasma cytokine levels were significantly higher after LPS, while increased IL-10 levels were
seen after anaphylaxis. After MCAo, both LPS and anaphylaxis increased microglial interleukin-1a (IL-1a) expression
and blood-brain barrier breakdown. LPS caused marked granulocyte recruitment throughout the ipsilateral
hemisphere. To investigate whether reduction of ischaemic damage can improve outcome in systemic
inflammation, controlled hypothermia was performed. Hypothermia reduced infarct size in all treatment groups
and moderately improved survival, but failed to reduce excess oedema formation after anaphylaxis and LPS-
induced neuroinflammation.
Conclusions: Our results suggest that systemic inflammatory conditions induce cerebrovascular inflammation via
diverse mechanisms. Increased brain inflammation, blood-brain barrier injury and brain oedema formation can be
major contributors to impaired outcome in mice after experimental stroke with systemic inflammatory stimuli,
independently of infarct size.
Keywords: cerebral ischaemia, blood-brain barrier, oedema, IL-1α, inflammation, systemic, LPS, anaphylaxis
* Correspondence: adam.denes@manchester.ac.uk
1Laboratory of Molecular Neuroendocrinology, Institute of Experimental
Medicine, Budapest, Hungary
Full list of author information is available at the end of the article
Dénes et al. Journal of Neuroinflammation 2011, 8:164
http://www.jneuroinflammation.com/content/8/1/164
JOURNAL OF 
NEUROINFLAMMATION
© 2011 Dénes et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Considerable research supports a relationship between
systemic inflammation and poor outcome in stroke
patients and in models of experimental stroke [1,2].
Animal models of co-morbidities in stroke have revealed
various systemic inflammatory mechanisms which con-
tribute to brain damage. These include peripheral
immune cells, proteases, cytokines and chemokines,
which can increase ischaemia-induced vascular perme-
ability, excitotoxicity and brain oedema resulting in
impaired blood flow recovery, leading to augmented
neuronal loss [3,4]. There is a correlation between the
size of ischaemic brain injury and the level of central
and peripheral inflammatory changes in experimental
animals, but this may not be translated easily to stroke
patients. It is partially due to the large variability of co-
morbidities, age, gender, time of admission after the
event and exposure to a wide array of different medi-
cines, which make the influence of systemic inflamma-
tion on outcome difficult to assess. In patients acute
infection, usually respiratory and of bacterial origin and
particularly in the week preceding stroke, is a significant
risk factor for cerebral infarction [1]. Inflammatory pro-
cesses other than infection are also associated with
worse otucome after stroke. For example, activation of
mast cells, a key cell type in allergy and anaphylaxis is
also linked to increased mortality and brain oedema in
stroke [5,6].
The treatment of patients with large hemispheric ischae-
mic stroke accompanied by massive space-occupying
oedema represents one of the major unsolved problems in
neurocritical care medicine [7]. Some clinical data indicate
that neuroprotective approaches may not be sufficient to
prevent brain oedema in cerebral ischaemia. For example,
hypothermia, a promising treatment for ischaemic stroke
due to its neuroprotective effect, was associated with an
increase in intracranial pressure and early mortality in a
high percentage of patients [7]. In experimental animals,
increase in infarct size mostly parallels increased brain
oedema and blood-brain barrier (BBB) breakdown, which
correlates with worse outcome. However, stroke patients
display large variability in recovery depending on location
of the infarct and differences in apparent comorbidities
[8,9]. This indicates that there is a need to understand the
mechanisms how clinically relevant inflammatory events
influence outcome after stroke. Therefore we asked
whether brain oedema, BBB injury and inflammation are
affected similarly by different systemic inflammatory chal-
lenges and whether reducing the size of the ischaemic
brain damage by hypothermia can lead to proportional
reduction of oedema and BBB damage during acute sys-
temic inflammatory conditions. Using two independent
peripheral inflammatory stimuli, endotoxin (LPS) and
anaphylaxis, in acute cerebral ischaemia in mice we
noticed that these conditions can be associated with
increased BBB breakdown, inflammation and brain
oedema, without significantly affecting infarct size. More-
over, infarct, but not brain oedema was significantly
reduced by hypothermia after anaphylactic challenge. Our
data indicate that circulating inflammatory markers in dif-
ferent acute systemic inflammatory conditions may worsen
outcome after focal cerebral ischaemia by directly increas-
ing BBB damage and brain oedema formation, with a
possible involvement of mediators other than most com-
monly measured cytokines.
Methods
Animals
Male, 8-14 weeks old C57BL/6 mice, weighing 25-30 g
were used for the study (n = 109). Mice were bred in
house, had free access to water and food and were main-
tained under temperature (21°C ± 1°C), humidity (65%)
and light-controlled conditions (12-h light/12-h dark
cycle, with lights on at 0700 hours). All animal procedures
were carried out in accordance with the European Com-
munities Council Directive (86/609 EEC) and Hungarian
Government directive 243/98. Experiments were approved
by the Institutional Animal Care and Use Committee at
the Institute of Experimental Medicine.
Systemic inflammatory challenge with Lipopolysaccharide
(LPS), ovalbumin sensitisation (OVA) and anaphylaxis
(OVA+A) prior to MCAo
Lipopolysaccharide (LPS, serotype: 0111:B4, Sigma L4391)
was administered intraperitoneally at doses of 100 μg/
mouse (4 mg/kg) 25 μg/mouse (1 mg/kg), 10 μg/mouse
(400 μg/kg) and 5 μg/mouse (200 μg/kg). The highest
doses (25-100 μg/mouse) were selected to induce substan-
tial systemic inflammation, without compromising survival
(LD50 value for LPS in mice after intraperitoneal adminis-
tration is 10-20 mg/kg [10,11]). No animals died or needed
to be terminated as a result of LPS injection alone in our
experiments. A separate group of mice were sensitised
intraperitoneally with 100 μg ovalbumin (Sigma A5378,
dissolved in 200 μl saline containing 1 mg Al(OH)3). Ana-
phylaxis was induced 14 days later via injection of 1 mg
ovalbumin intraperitoneally (ip.) or intravenously (iv.).
Mice were subjected to MCAo 3 h after LPS or anaphylac-
tic challenge.
Transient focal cerebral ischaemia
Middle cerebral artery occlusion (MCAo) was performed
using the intraluminal filament technique as described
previously [12]. Anaesthesia was induced with 2%
halothane and maintained in 1% halothane-air mixture.
For normothermic experiments, core temperature was
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0.5°C, using a homeothermic blanket during the surgery.
For controlled hypothermia, unheated, anaesthetised mice
were allowed to spontaneously lose temperature during
the surgery until reaching 33 ± 0.5°C and then body tem-
perature was maintained between 33-34°C during occlu-
sion. MCAo was performed with a nylon filament (tip
diameter 180 μm, silicone coated), which was introduced
into the origin of the external carotid artery and advanced
through the internal carotid artery to occlude the MCA.
After 60 minutes of occlusion, reperfusion was induced
and both normothermic and hypothermic mice were kept
at 27°C for 4 h before returning to normal housing. Sham
surgery was performed exactly the same as MCAo, but the
filament was immediately withdrawn after reaching the
origin of the MCA. Mice were subcutaneously injected
with 1 mL of sterile saline after the surgery and continu-
ously monitored for neurologic symptoms. Animals were
euthanised if they were unable to move spontaneously
after 3 h recovery period, or if breathing was seriously
compromised. Otherwise, mice were terminated after 24 h
reperfusion. Due to the mild to moderate sickness beha-
viour seen after systemic LPS and anaphylaxis, induction
of ischaemia blinded to treatment groups was not fully
possible.
Histology
Mice were anaesthetised and perfused transcardially with
10 mL saline followed by 40 mL 4% paraformaldehyde in
0.1 M Phosphate buffer (pH = 7.4). After cryoprotection
of brains in 20% sucrose-KPBS for 24 h, five alternate sets
of 20 μm coronal brain sections were cut on a sledge
microtome. All sections were collected in an anti-freeze
solution (30% ethylene glycol and 20% glycerol in phos-
phate-buffered saline) and stored at -20°C until processing.
Measurement of infarct volume and BBB damage
The volume of ischaemic damage was measured using a
modification of a method described previously [12]. Briefly,
areas of ischaemic damage were identified on cresyl-violet-
stained sections at eight neuroanatomically defined coronal
levels. Digitized images were created and the areas of
damage measured using ImageJ software (NIH, Bethesda,
MD, USA). The volume of damage was calculated by inte-
gration of areas of damage with the distance between coro-
nal levels. The end points for integration were 2.9 mm
(rostral limit) and -4.9 mm (caudal limit) relative to
bregma. Volumes are expressed as a percentage of the total
hemispheric volume. Leakage of plasma derived IgG into
the brain parenchyma was detected by biotinylated horse
anti-mouse IgG (Vector Laboratories, BA-2000, 1:500) fol-
lowing blocking nonspecific binding in 5% normal horse
serum and 1% BSA. After 30 min incubation with ABC
solution (1:500, Vector Laboratories) the reaction was
developed with 3,3’-diaminobenzidine (DAB). The volume
of BBB damage was calculated as described above. Brain
oedema was measured on cresyl violet-stained brain sec-
tions and was expressed as a percentage increase of the
volume of the ipsilateral hemisphere compared to the con-
tralateral side.
Immunofluorescence
Free-floating brain sections were blocked with 2% normal
donkey serum and incubated overnight with primary anti-
bodies: goat anti-IL-1a (R&D Systems, AF-400-NA) and
rabbit anti-granulocyte serum (SJC, kindly provided by
Drs. Daniel Anthony and Sandra Campbell, University of
Oxford). Then, donkey anti-goat Alexa 488 and donkey
anti-rabbit Alexa 594 fluorescent secondary antibodies
were used. Sections were stained with biotinylated tomato
lectin, which was visualised with streptavidin Alexa 350
conjugate.
In Situ Hybridization Histochemistry
To monitor IL-1b mRNA, a riboprobe complementary to
373 to 940 nucleotides of the mouse IL-1b gene was tran-
scribed from plasmid (S. Ferenczi) in the presence of
35S-UTP. Tissue sections were mounted onto SuperFrost
Ultra Plus (Menzer-Glazer) slides post-fixed with 4%
paraformaldehyde, digested with Proteinase K (10 in
50 mmol/L Tris, pH = 8 and 5 mmol/L EDTA at 37°C,
5 mins), acetylated (0.25% acetic anhydride in 0.1 mol/L
triethanolamine, pH = 8), and dehydrated. Hybridization
mixture (50% formamide, 0.3m o l / LN a C l ,1 0m m o l / L
Tris (pH = 8), 2 mmol/L EDTA, 1X Denhardt’s, 10% dex-
tran sulfate, 0.5 mg/mL yeast tRNA) was pipetted onto the
slides (100 mL, containing probe at 10
7 d.p.m./mL) and
hybridized overnight at 56°C. Sections were then rinsed in
4X SSC (1X SSC: 0.15 mol/L NaCl and 15 mmol/L triso-
diumcitrate buffer, pH = 7), digested with ribonuclease A
(20 mg/mL in Tris-EDTA buffer with 0.5 mol/L NaCl at
37°C for 30 min), gradually desalted, and washed in 0.1X
SSC at 65 to 75°C for 30 min. Slides were dipped in NTB
nuclear emulsion (Kodak) and exposed for 2 weeks, devel-
oped in D-19 developer, and lightly counterstained with
cresyl violet.
Quantitative Real-Time PCR
Total RNA was isolated from brain samples with QIA-
GEN RNeasy Mini Kit (Qiagen, Valencia, CA, USA)
according the manufacturer’s instruction. To eliminate
genomic DNA contamination DNase I treatment was
used (100 μl Rnase-free DNase I (1u DNase) solution
(Fermentas) was added. Sample quality control and the
quantitative analysis were carried out by NanoDrop
(Thermo Scientific). Amplification was not detected in
the RT-minus controls. cDNA synthesis was performed
with the High Capacity cDNA Reverse Transcription Kit
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designed primers (Invitrogen, Table 1) were used in the
Real-Time PCR reaction with Fast EvaGreen qPCR Mas-
ter Mix (Biotium, CA, USA) on ABI StepOnePlus instru-
ment. Gene expression was analyzed by ABI StepOne 2.1
program. The amplicon was tested by Melt Curve Analy-
sis on ABI StepOnePlus instrument. GAPDH and ß-actin
were used as endogenous control reference genes.
Experiments were normalized to GAPDH expression.
Measurement of plasma IL-1b and OVA-specific IgE by
ELISA
Blood was taken from the right heart ventricle immediately
before transcardial perfusion. 3.8% sodium citrate (1:10)
was used as an anticoagulant. IL-1b was measured by using
mouse IL-1 beta/IL-1F2 DuoSet ELISA kit (DY401, R&D
Systems) according to the manufacturers protocol. For the
measurement of OVA-specific IgE, Nunc-Immuno
™ plates
(Sigma) were coated with plasma samples in bicarbonate
coating buffer (0.1 M NaHCO3, 0.1 M NaCl, pH 8.2) and
then blocked with 1% BSA in PBS. Biotinylated anti-mouse
IgE antibody was used to detect plasma OVA-specific IgE
and mouse anti-ovalbumin IgE (Serotec, MCA2259) anti-
body was used as standard. The reaction was developed
with SAV-HRP (R&D Systems) followed by OptEIA™
TMB Substrate Reagent Set (BD Biosciences).
Cytokine measurements with cytometric bead array (CBA)
Plasma samples were analysed for 11 key inflammatory
cytokines (G-CSF, IFNg,I L - 1 b,I L - 1 a, IL-10, IL-17, IL-6,
K C ,M C P - 1 ,T N F a, RANTES) by using appropriate CBA
Flex Sets (BD Biosciences) according to the manufacturer’s
protocol. To measure the same cytokines in brain homoge-
nates, animals were transcardially perfused with saline
3 hours after systemic inflammatory challenges. Brain
hemispheres were homogenised as described elsewhere
[13].
Data analysis
Quantitative analysis was done in a blinded manner
whenever it was possible. Data were analysed by using
One-way or Two-way analysis of variance (ANOVA) fol-
lowed by Bonferroni’s post hoc multiple- or paired com-
parison. Data are expressed as mean ± SEM.
Results
Systemic inflammation impairs survival after experimental
stroke
Mice were challenged with LPS or Ova+A 3 h before
MCAo to develop a systemic inflammatory response
[14-17] by the time experimental stroke was induced.
Mice injected with LPS (25-100 μg/mouse) displayed mild
to moderate sickness behaviour, respectively, which was
less pronounced at doses of 5-10 μg. Ova sensitised mice
showed signs of ear swelling and itching after anaphylactic
challenge, which largely resolved after 1-2 h. Successful
sensitisation against Ova was confirmed by elevated circu-
lating Ova-specific IgE levels (Figure 1A). Plasma IL-1b
was upregulated in LPS-treated animals (Figure 1B), indi-
cating the development of a systemic inflammatory
response. Only actively moving animals which showed no
signs of serious illness 3 h after LPS or Ova+A challenge
were subjected to 60 min MCAo.
Mice challenged intraperitoneally with Ova+A showed
impaired recovery after MCAo and only 56% of mice sur-
vived for 24 h (Figure 1C). However, 75% of the animals
survived if mice were challenged with intravenous Ova
indicating that Ova is likely to be acting locally on sensi-
tised peritoneal cells to initiate a systemic inflammatory
response, compromising survival after experimental
Table 1 Primers used for real-time PCR
FORWARD REVERSE R
2 EFF (%)
GAPDH TGACGTGCCGCCTGGAGAAA AGTGTAGCCCAAGATGCCCTTCAG 0,996 91,7
ACTIN-b CGTAAAGACCTCTATGCCAA GCGCAAGTTAGGTTTTGTC 0,988 92,5
IL-1b GCCTCGTGCTGTCGGACCCA TGAGGCCCAAGGCCACAGGT 0,953 98,1
IL-1a CCATAACCCATGATCTGGAAGAG GCTTCATCAGTTTGTATCTCAAATCAC 0,998 104,0
IL-17a CCTGGCGGCTACAGTGAAG GGAAGTCCTTGGCCTCAGTGT 0,959 95,8
IL-6 CAGTTGCCTTCTTGGGACTGA GGGAGTGGTATCCTCTGTGAAGTCT 0,959 108,0
IL-10 AGTGAGAAGCTGAAGACCCTCAGG TTCATGGCCTTGTAGACACCTTGGT 0,970 107,2
G-CSF TGCCCAGAGGCGCATGAAGC GGGGAACGGCCTCTCGTCCT 0,997 102,5
MCP-1 CCAGCACCAGCACCAGCCAA TGGATGCTCCAGCCGGCAAC 0,967 94,8
TNFa CAGCCGATGGGTTGTACCTT GGCAGCCTTGTCCCTTGA 0,985 102,4
KC GAGCTGCGCTGTCAGTGCCT CAAGGCAAGCCTCGCGACCA 0,997 105,2
Primers used for real-time PCR (comparative CT experiments) were designed by the Primer Express 3.0 program. Oligonucleotide primer sequences, R2
(regression coefficient) and efficiency (eff %) of the PCR reactions are listed for all primer pairs.
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Page 4 of 13Figure 1 Systemic inflammatory challenges compromise survival after experimental stroke. A. Measurement of Ova-specific IgGE in
plasma with ELISA confirms proper sensitization to antigen in Ova injected mice without (Ova) and with (Ova+A) anaplylaxis. B. Plasma IL-1b
levels were determined with ELISA after 60 min MCAo and 24 h reperfusion. C. Percentage values show the average survival rate of mice at 24 h
reperfusion after various challenges and MCAo or sham surgery. Anaphylaxis induced by intraperitoneal (i.p.), intravenous (i.v.) Ova administration
in sensitized mice. Systemic inflammation induced by i.p. LPS injection 3 hours prior to MCAo profoundly increase mortality within 24 hours (n =
4-11/group). One-way ANOVA followed by Bonferroni’s comparison (*P < 0.05 vs Control).
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expressed no mortality during these studies after MCAo.
No mice survived after MCAo if they received 25-100 μg
LPS. Very poor recovery and high mortality (50-60%) was
observed with 5-10 μg LPS after MCAo, whereas even
high doses of LPS did not compromise survival after sham
surgery (Figure 1C). These data showed that circulating
inflammatory mediators induced by two completely differ-
ent stimuli can profoundly impair survival after experi-
mental stroke.
Systemic inflammatory challenges augment
cerebrovascular inflammation, BBB damage and brain
oedema after experimental stroke, independently of
infarct size
Mice that survived for 24 h were investigated to reveal
how different systemic stimuli affected brain damage
caused by focal cerebral ischaemia. No significant
increase of ischaemic brain damage was observed after
LPS or Ova+A challenges (Figure 2A). However, both
conditions increased BBB damage (Figure 2B). Systemic
inflammation resulted in increased brain oedema (sys-
temic inflammatory challenges versus control condi-
tions, P < 0.05, Two-way ANOVA). Sensitisation with
Ova without anaphylaxis did not have any detrimental
effect on oedema or BBB damage (Figure 2B-D). Next,
we examined whether different systemic inflammatory
conditions had an effect on brain inflammation after
MCAo. Anaphylaxis significantly increased the expres-
sion of IL-1a in the ipsilateral cerebral cortex (Figure
3A, C), while endotoxin-induced systemic response was
associated with profound increases of IL-1a in remote
areas, such as the thalamus and the hypothalamus (P <
0.05). In addition to parenchymal cells, several IL-1a-
positive cells were observed perivascularly around
dilated blood vessels after anaphylaxis, indicating that
IL-1a expression may be associated with the develop-
ment of vasogenic oedema (Figure 3C, i). In contrast,
LPS-treated mice displayed mostly parenchymal, elon-
gated, IL-1a-positive cells with microglial morphology
Figure 2 Systemic inflammation increases BBB damage and brain oedema independently of infarct size. A. The volume of the ischaemic
damage was measured on cresyl violet (Nissl) stained serial brain sections. B. BBB damage was assessed by immunostaining for mouse IgG on
free floating brain sections. Intraperitoneal LPS injection and anaphylaxis 3 hours prior to MCAo significantly augment BBB disruption at 24 hours
of reperfusion (P < 0.05, One-way ANOVA, Bonferroni’s post-hoc comparison). C. Oedema is expressed as percentage increase of the ipsilateral
hemispheric volume compared to the contralateral hemisphere (# P < 0.05, systemic inflammatory challenges versus control conditions, Two-way
ANOVA). D. Representative images show the ischaemic brain- (Nissl) or BBB (IgG) damage in different treatment groups. Data are representative
of 4-5 mice/group.
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Page 6 of 13Figure 3 Experimental stroke-induced IL-1 expression is increased in the brain after LPS administration and anaphylaxis. Quantification
of IL-1a-positive cells (A) and granulocytes (B) in the ipsilateral hemisphere. C. Immunofluorescence shows IL-1a-positive cells (green),
granulocytes (red) and tomato lectin-positive blood vessels (blue) and microglia/macrophage cells in the ipsilateral cerebral cortex and thalamus
after 24 h reperfusion. Perivascular cells in the cerebral cortex (i) and parenchymal cells in the thalamus (ii) expressing IL-1a after MCAo are
abundant in mice with anaphylaxis and LPS treatment, respectively. D. In situ hybridization reveals increased number of cells expressing IL-1b
mRNA in the ischaemic cerebral cortex of mice 24 h after MCAo with anaphylaxis (Ova+A) compared to MCAo and Ova sensitization (Ova). E.
Silver grains indicate the presence of IL-1 b mRNA in Ova and Ova+A mice after MCAo (counterstained with cresyl violet). Inserts show higher
magnification of IL-1b mRNA containing cells indicated by arrowheads. Data are representative of 4-5 mice in each group. One-way ANOVA
followed by Bonferroni’s comparison (P < 0.05 vs * Control, # Ova, $ Ova+A). Scale bars: Cii - 20 μm, C -5 0μm, E - 100 μm.
Dénes et al. Journal of Neuroinflammation 2011, 8:164
http://www.jneuroinflammation.com/content/8/1/164
Page 7 of 13(Figure 3C, ii). IL-1a expression was detected mostly in
tomato lectin-positive ramified microglia/macrophage
cells (not shown). LPS treatment resulted in an overall
increase of granulocytes in the ipsilateral hemisphere
(P < 0.05), whereas this was only observed in the cere-
bral cortex after anaphylaxis (Figure 3B, C).
We also measured IL-1b expression in the brain after
MCAo, using in situ hybridization. IL-1b has been asso-
ciated with brain oedema formation after stroke
[4,18-20]. We did not find significant changes in IL-1b
mRNA expression after MCAo in LPS-treated mice
(data not shown) compared to controls, but observed
markedly increased numbers of IL-1b mRNA expressing
cells after anaphylaxis (Figure 3D, E). In line with the
IL-1a data, IL-1b mRNA expression was augmented
mostly in the ischaemic cerebral cortex (Figure 3B, C) at
24 h reperfusion, whereas we only occasionally observed
IL-1b-positive cells in the ipsilateral striatum (data not
shown).
LPS and anaphylaxis-induced systemic inflammatory
responses are dominated by different circulating
cytokines
To investigate whether these fundamentally different
systemic inflammatory stimuli drive different systemic
inflammatory responses, we investigated the plasma
levels of 11 key cytokines 3 h after LPS or anaphylaxis
(at the time MCAo is performed). LPS induced pro-
found (10-1000 fold) increases in G-CSF, IL-6, KC,
MCP-1, TNFa, and RANTES and a 4-fold, but signifi-
cant increase in IL-1b, without significantly affecting
IFNg,I L - 1 7 A ,I L - 1 a and IL-10 levels (Figure 4). Ana-
phylaxis increased G-CSF, IL-6, KC, MCP-1, TNFa, and
RANTES levels 4-30 fold (not significant), and signifi-
cantly elevated IL-10 levels (80 fold) while no IL-1b or
IL-1a was detected (Figure 4).
Systemic inflammatory challenges induce
neuroinflammatory changes in the brain
In order to examine inflammatory changes in the brain in
response to systemic inflammatory challenges, we mea-
sured central IL-1a,I L - 1 b and IL-10 expression with real-
time PCR, 3 h after LPS treatment or anaphylaxis. In the
absence of any direct brain injury, intraperitoneal LPS
caused a 2-3 fold increase in central IL-1a and IL-1b
mRNA levels in brain hemishpheres compared to control
mice (Figure 5A). In contrast, IL-10 mRNA levels were
decreased in LPS and Ova treated mice and after anaphy-
laxis compared to controls (Figure 5A).
Cytometric bead array did not show significant eleva-
tion in IL-1a,I L - 1 b or IL-10 protein concentration in
the brain after LPS administration or anaphylaxis (data
not shown), but revealed a significant increase in MCP-1
(6 fold), RANTES (3-4 fold), G-CSF (17 fold) and IL-6
(9 fold) levels in response to LPS (Figure 5B). KC
(CXCL-1) was elevated in the brain 2-40 fold after LPS
treatment, which was not significant due to large varia-
tions among individual animals (data not shown).
Real-time PCR confirmed the induction of MCP-1,
G-CSF, and KC in the brain after intraperitoneal LPS
treatment and also revealed higher levels of TNFa mRNA
compared to control mice (Figure 5C). Interestingly, IL-6
mRNA levels were significantly reduced after LPS admin-
istration (Figure 5C).
Hypothermia profoundly reduces ischaemic brain injury,
but does not prevent the effect of systemic inflammation
on brain oedema and survival
To further investigate the mechanisms of how peripheral
inflammatory challenges affect ischaemic brain damage
and inflammation, we subjected mice to hypothermia dur-
ing occlusion, using the same experimental groups as
above. Overall, hypothermia profoundly reduced ischaemic
brain damage (P < 0.001) and brain oedema (P < 0.01)
compared to normothermia (Figure 6A, B). Only LPS-trea-
ted mice showed elevated granulocyte levels and IL-1a
expressing cells in the ipsilateral hemisphere after
hypothermia and MCAo (not shown), indicating that
peripheral LPS initiates brain inflammation even if the
ischaemic brain damage is reduced. Hypothermia was
not sufficient to protect against increased brain oedema
caused by anaphylaxis compared to control mice (Figure
6C). Moreover, hypothermia only moderately reduced
mortality in mice exposed to LPS or anaphylaxis (72% sur-
vival after LPS and 67% survival after anaphylaxis).
Discussion
Here we present experimental evidence that two different
systemic inflammatory conditions, endotoxin treatment
and anaphylaxis markedly compromise survival, augment
brain oedema, BBB damage and cerebrovascular inflam-
mation after experimental cerebral ischaemia. We also
show that this effect is not a direct consequence of
increased ischaemic brain damage in the current model,
and reduction of the infarct by hypothermia cannot fully
prevent increased mortality (after both LPS and anaphy-
laxis) and oedema (after anaphylaxis). The key message of
our study is that a number of complications associated
with systemic inflammation in stroke patients may be in
part caused by an elevated inflammatory burden and not
only consequences of a large infarct in response to pre-
existing inflammation or infection.
Our aim was to investigate the effect of two acute sys-
temic inflammatory conditions, which involve fundamen-
tally different mechanisms of induction, on brain injury
and survival. LPS stimulates toll-like receptor 4 (TLR4),
which results in the release of key proinflammatory cyto-
kines from various cell types [21]. Elevated levels of IL-1b,
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Page 8 of 13TNFa and IL-6 have been reported in the circulation,
while IL-6 can also be detected in the cerebrospinal fluid
(CSF) within 2-5 h after intaperitoneal LPS administration
[15,22]. We found high levels of circulating inflammatory
cytokines and elevated IL-1b levels 3 h after LPS challenge,
the time when MCAo was induced. It is likely that
activation of TLR4 by host-derived ligands can also impact
on stroke outcome as TLR4-deficient mice are protected
against the ischaemic injury [23]. The classic pathway of
systemic anaphylaxis is induced largely by activation of
mast cells and results in the release of various vasoactive
and inflammatory mediators, such as histamine and
Figure 4 Cytokine responses in the plasma after systemic inflammatory challenges. Cytokines in plasma samples were measured by
cytometric bead array. Mean ± SEM values are shown, n = 3-7. One-way ANOVA followed by Bonferroni’s comparison (P < 0.05 vs * Control, # Ova).
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Page 9 of 13platelet-activating factor [24]. In our study, successful acti-
vation of Ova-sensitized mast cells was also indicated by
elevated levels of IL-10 [25]. Mast cells are early respon-
ders to stroke and are involved in the regulation of acute
BBB changes after cerebral ischaemia [6]. Inhibition of
mast cell function reduces brain oedema formation after
intracerebral haemorrhage [26]. Therefore, our data show
that the induction of systemic inflammation was successful
with two independent models, which are both relevant to
ischaemic stroke.
It is generally difficult to evaluate the exact mechanisms
whereby systemic inflammation affects ischaemic brain
injury in experimental studies, because larger strokes are
mostly associated with elevated levels of inflammation in
the brain. The key finding of our study was the profound
effect of systemic inflammatory challenges on survival and
Figure 5 Systemic inflammatory challenges induce neuroinflammatory changes in the brain. A. In homogenates of brain hemispheres,
real-time PCR reveals changes in cytokine expression 3 h after intraperitoneal LPS administration or anaphylaxis. Values represent fold changes
over control. B. Cytometric bead array shows increased cytokine levels in the brain 3 hours after LPS treatment. C. Elevated cytokine mRNA levels
confirm central induction of inflammation after peripheral LPS treatment. Cytokine expression was analysed with real-time PCR in brain
hemisphere samples. Data are representative of 3-7 mice in each group. One-way ANOVA followed by Bonferroni’s post-hoc comparison (*P <
0.05, **P < 0.01).
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Page 10 of 13brain inflammation after stroke, which took place indepen-
dently of the increase in infarct size. Moreover, both con-
ditions (LPS and anaphylaxis) increased BBB damage
compared to control animals, which is likely to contribute
to the formation of brain oedema. Peripherally adminis-
tered LPS has minimal penetration across the murine
blood-brain barrier [27] but LPS and circulating inflamma-
tory mediators can induce central inflammatory actions
through receptors expressed in the circumventricular
organs [28,29]. Our data show that central inflammatory
responses have been altered due to systemic LPS challenge
and anaphylaxis prior to the induction of experimental
stroke. Increased BBB damage, brain oedema and the
induction of IL-1a in the hypothalamus, thalamus and in
perivascular macrophages/microglia after MCAo in
response to LPS might be associated with direct effects of
LPS on circumventricular organs or signals mediated by
perivascular receptors of LPS and/or other inflammatory
mediators. A previous study showed low mortality, but
increased ischaemic- and BBB damage after MCAo and
intraperitoneal LPS administration compared to MCAo
alone [18]. However, in that study the time of LPS admin-
istration was 30 min, and not 3 h prior to MCAo as in our
model, which may result in different systemic levels of
proinflammatory mediators by the time MCAo is per-
formed. In contrast, intraperitoneal IL-1b administration
was found to increase mortality by 60% [18], which is
strikingly similar to what we observed after LPS challenge.
Analysis of central cytokine changes indicated an
altered inflammatory statusi nt h eb r a i na f t e rs y s t e m i c
inflammatory challenges. The induction of IL-1a,I L - 1 b,
TNFa M C P - 1 ,R A N T E S ,G - C S F ,K Cm R N Aa n d
increased MCP-1, RANTES, G-CSF protein levels in the
brain after systemic LPS challenge are likely to result in a
primed proinflammatory response by the time experi-
mental stroke is induced. This, together with altered
IL-10 mRNA levels after both anaphylaxis and LPS may
partially explain elevated microglia-derived IL-1,
increased brain oedema and BBB damage seen after
MCAo. The downregulation of IL-6 mRNA and the
increase in IL-6 protein levels 3 h after LPS administra-
tion are controversial and may indicate a complex and
time-dependent regulation of central inflammatory
responses at mRNA and peptide levels by systemic
challenges.
To our knowledge, no studies have investigated the
effect of anaphylaxis on experimental stroke so far. We
show that anaphylaxis profoundly impaired survival in
Figure 6 Hypothermia reduces brain injury but does not prevent increased brain oedema formation after anaphylaxis. Hypothermia
combined with 60 minutes of MCAo results in profound protection against ischaemia in all animal groups compared to normothermia (P <
0.001, see Figure 2). Body temperature was reduced to 33°C by spontaneous heat loss during surgery and was maintained between 33-34°C
during occlusion. A. The volume of the ischaemic damage was measured on cresyl violet (Nissl) stained serial brain sections (B). C. Anaphylaxis
significantly increases brain oedema after MCAo and 24 hours of reperfusion compared to Ova sensitization (P < 0.05, One-way ANOVA,
Bonferroni’s post-hoc comparison) in hypothermic mice with 60 minutes of MCAo. Data are representative of 5 mice/group. n.s.- not significant.
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Page 11 of 13the same time frame as LPS treatment did, in spite of
the fundamentally different mechanisms of induction as
outlined above. After anaphylaxis, we found upregula-
tion of several proinflammatory cytokines, although high
levels of circulating IL-10 were measured. IL-10 protects
against brain injury [30,31], which may explain why we
did not observe an increase in infarct volume after
MCAo in these mice. In contrast, high numbers of IL-
1a-immunopositive and IL-1b mRNA expressing cells
and dilated blood vessels were seen in the brain after
anaphylaxis and MCAo, which indicates that these
changes were initiated in response to systemic inflam-
matory challenge. Anaphylaxis may exert its effects on
brain inflammation through other inflammatory media-
tors than the cytokines examined. Although LPS
increased proinflammatory cytokines several fold com-
pared to anaphylactic challenge and initiated a more
pronounced granulocyte response, IL-1a-positive cells
after endotoxin treatment were dominantly expressed in
remote areas. However, our data show that both LPS
and anaphylaxis result in the release of various vasoac-
tive substances into the circulation, which can alter vas-
cular permeability and therefore lead to oedema in
central and peripheral tissues [32-35].
One possible explanation for not observing increased
infarct volume in these studies may be the loss of the most
serious cases prior to 24 h reperfusion, which could result
in increased numbers of mice with smaller infarct after
systemic inflammatory challenge. However, in our hands
the current MCAo model did not result in maximal corti-
cal damage in any of the treatment groups (Figure 2),
which argues against this explanation. To further examine
mechanisms whereby systemic inflammatory challenges
affect brain injury, we also repeated MCAo and all treat-
ments under hypothermic conditions. Although we found
significant protection with respect to ischaemic brain
damage by hypothermia in all groups, mice that under-
went anaphylaxis and MCAo displayed increased brain
oedema compared to controls. Hypothermia has been
shown to exert neuroprotection and can markedly reduce
infarct size in experimental rodent models [36,37]. How-
ever, our data indicate that at least in part, brain oedema
may be directly affected by circulating inflammatory med-
iators and is not only a consequence of increased brain
damage after stroke with systemic anaphylaxis. These
results indicate the need for precise understanding of the
effect of systemic inflammatory changes on oedema for-
mation after stroke. Systemic inflammation is not only a
predictor to worse outcome in stroke patients [2,3] but
anaphylactoid reactions may occur in response to throm-
bolytic treatment in stroke patients taking an angiotensin-
converting-enzyme inhibitor [38,39]. Cerebral ischaemia
can also occur in patients after wasp sting anaphylaxis
[40,41] indicating that changes in blood coagulation may
be involved in this process.
Taken together, these data demonstrate the involve-
ment of acute systemic inflammation in increased mor-
tality, BBB damage and brain oedema formation after
experimental stroke. The fact that these changes are not
neccessarily linked to increased ischaemic brain damage
indicate that appropriate management of stroke patient
with various comorbidities in the future may require
precise understanding of the interaction between periph-
eral inflammatory processes and cerebral ischaemia.
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